Femasys up on completing enrollment for birth control solution trial
06/10/2022 15:41
** Shares of Femasys Inc FEMY.O gain ~5% to $1.21
** Company says it has completed enrollment for a mid-stage
study of its nonsurgical solution, FemBloc, in development for
permanent birth control urn:newsml:reuters.com:*:nGNX71X8kK
** FemBloc method seeks to prevent pregnancy by causing
fallopian tubes to close over time using a liquid, which is put
through a thin plastic tube placed into uterus
** Including session's gain, stock down 69% YTD
(Reporting by Raghav Mahobe)
((Raghav.Mahobe@thomsonreuters.com;))